

Matthew Cooperberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9259312/publications.pdf>

Version: 2024-02-01

550
papers

25,795
citations

9756

73
h-index

9073

144
g-index

566
all docs

566
docs citations

566
times ranked

20589
citing authors

#	ARTICLE	IF	CITATIONS
1	Sexual function outcomes of radiation and androgen deprivation therapy for localized prostate cancer in men with good baseline function. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 238-247.	2.0	2
2	Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium. <i>Journal of Urology</i> , 2022, 207, 127-136.	0.2	7
3	Active surveillance in intermediate-risk prostate cancer with PSA 10-20 ng/mL: pathological outcome analysis of a population-level database. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 690-693.	2.0	8
4	Association between Delay to Radical Prostatectomy and Clinically Meaningful Outcomes among Patients with Intermediate and High-Risk Localized Prostate Cancer. <i>Journal of Urology</i> , 2022, 207, 592-600.	0.2	6
5	Optimization of prostate biopsy - Micro-Ultrasound versus MRI (OPTIMUM): A 3-arm randomized controlled trial evaluating the role of 29 MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer. <i>Contemporary Clinical Trials</i> , 2022, 112, 106618.	0.8	24
6	Hyperpolarized 1-[13C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Immune Checkpoint Inhibitor Therapy in Prostate Cancer. <i>European Urology</i> , 2022, 81, 219-221.	0.9	17
7	Molecular risk classifier score and biochemical recurrence risk are associated with cribriform pattern type in Gleason 3+4=7 prostate cancer. <i>Investigative and Clinical Urology</i> , 2022, 63, 27.	1.0	8
8	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. <i>Human Genetics and Genomics Advances</i> , 2022, 3, 100070.	1.0	10
9	Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. <i>JAMA Oncology</i> , 2022, 8, 41.	3.4	25
10	Association of Treatment Modality, Functional Outcomes, and Baseline Characteristics With Treatment-Related Regret Among Men With Localized Prostate Cancer. <i>JAMA Oncology</i> , 2022, 8, 50.	3.4	45
11	Active Surveillance: Very Much Preferred for Low-Risk Prostate Cancer. <i>Journal of Urology</i> , 2022, 207, 262-264.	0.2	3
12	Androgen Deprivation Therapy and the Risk of Dementia after Treatment for Prostate Cancer. <i>Journal of Urology</i> , 2022, 207, 832-840.	0.2	8
13	Association between Treatment for Localized Prostate Cancer and Mental Health Outcomes. <i>Journal of Urology</i> , 2022, 207, 1029-1037.	0.2	9
14	The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate Cancer. <i>Journal of Urology</i> , 2022, 207, 1001-1009.	0.2	3
15	Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for large cribriform prostatic adenocarcinoma. <i>Modern Pathology</i> , 2022, 35, 1092-1100.	2.9	10
16	Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer. <i>European Urology Open Science</i> , 2022, 37, 113-119.	0.2	10
17	Red Blood Cell Distribution Width Is Associated with All-cause Mortality but Not Adverse Cancer-specific Outcomes in Men with Clinically Localized Prostate Cancer Treated with Radical Prostatectomy: Findings Based on a Multicenter Shared Equal Access Regional Cancer Hospital Registry. <i>European Urology Open Science</i> , 2022, 37, 106-112.	0.2	5
18	Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, , .	2.0	0

#	ARTICLE	IF	CITATIONS
19	Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. <i>European Urology</i> , 2022, 82, 341-351.	0.9	32
20	Predictors of Regret among Older Men after Stress Urinary Incontinence Treatment Decisions. <i>Journal of Urology</i> , 2022, 207, 885-892.	0.2	5
21	Prostate weight and prostate cancer outcomes after radical prostatectomy: Results from the SEARCH cohort study. <i>Prostate</i> , 2022, 82, 366-372.	1.2	3
22	Low-Grade Prostate Cancer: Time to Stop Calling It Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3110-3114.	0.8	41
23	How Often Does Magnetic Resonance Imaging Detect Prostate Cancer Missed by Transrectal Ultrasound?. <i>European Urology Focus</i> , 2021, 7, 1268-1273.	1.6	6
24	Prospective validation of microseminoprotein α^2 added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohort. <i>BJU International</i> , 2021, 128, 218-224.	1.3	3
25	Monitoring Prostate Cancer Incidence Trends: Value of Multiple Imputation and Delay Adjustment to Discern Disparities in Stage-specific Trends. <i>European Urology</i> , 2021, 79, 42-43.	0.9	2
26	Reply to Yi Sun, Fengxiang Sun, Qiang Wei, Jin Huang, and Ruiqi Duan's Letter to the Editor re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. <i>Eur Urol</i> 2020;78:304-6. <i>European Urology</i> , 2021, 79, e16.	0.9	0
27	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. <i>European Urology</i> , 2021, 79, 374-383.	0.9	93
28	Liposomal Bupivacaine Decreases Postoperative Length of Stay and Opioid Use in Patients Undergoing Radical Cystectomy. <i>Urology</i> , 2021, 149, 168-173.	0.5	6
29	Do Hispanic Men Have Worse Outcomes After Radical Prostatectomy? Results From SEARCH. <i>Urology</i> , 2021, 149, 181-186.	0.5	3
30	Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes. <i>European Urology</i> , 2021, 79, 141-149.	0.9	4
31	Association Between Twitter Reception at a National Urology Conference and Future Publication Status. <i>European Urology Focus</i> , 2021, 7, 214-220.	1.6	12
32	Monocyte counts and prostate cancer outcomes in white and black men: results from the SEARCH database. <i>Cancer Causes and Control</i> , 2021, 32, 189-197.	0.8	1
33	The Gender Pay Gap in Urology. <i>Urology Practice</i> , 2021, 8, 149-154.	0.2	8
34	Single-cell analysis of cellular state heterogeneity in human localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 254-254.	0.8	0
35	Reply by Authors. <i>Journal of Urology</i> , 2021, 205, 339-340.	0.2	1
36	Clinical Utility of 4Kscore [®] , ExosomeDx [®] , and Magnetic Resonance Imaging for the Early Detection of High Grade Prostate Cancer. <i>Journal of Urology</i> , 2021, 205, 452-460.	0.2	36

#	ARTICLE	IF	CITATIONS
37	Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer. <i>Cancer</i> , 2021, 127, 1912-1925.	2.0	6
38	Characteristics of Participants in the American Urological Association Quality (AQUA) Registry and Early Impact of Participation on Quality of Care. <i>Urology Practice</i> , 2021, 8, 209-216.	0.2	3
39	Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population. <i>Prostate</i> , 2021, 81, 390-397.	1.2	5
40	The Impact of Comorbidity and Age on Timing of Androgen Deprivation Therapy in Men with Biochemical Recurrence after Radical Prostatectomy. <i>Urology Practice</i> , 2021, 8, 238-245.	0.2	1
41	Patient-Reported Financial Toxicity Associated with Contemporary Treatment for Localized Prostate Cancer. <i>Journal of Urology</i> , 2021, 205, 761-768.	0.2	21
42	Diabetes and Prostate Cancer Outcomes in Obese and Nonobese Men After Radical Prostatectomy. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab023.	1.4	13
43	Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4367.	1.8	62
44	SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study. <i>Cancers</i> , 2021, 13, 2047.	1.7	45
45	Incidental Prostate Cancer (cT1a-cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines. <i>European Urology Oncology</i> , 2021, , .	2.6	6
46	Time Trends in Use of Radical Prostatectomy by Tumor Risk and Life Expectancy in a National Veterans Affairs Cohort. <i>JAMA Network Open</i> , 2021, 4, e2112214.	2.8	8
47	Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. <i>European Urology</i> , 2021, 79, 717-721.	0.9	13
48	Reply to Nicolas Mottet, Olivier Rouviere, and Theodorus H. van der Kwast. Incidental Prostate Cancer: A Real Need for Expansion in Guidelines? <i>Eur Urol Oncol</i> . In press. <i>European Urology Oncology</i> , 2021, 5, 261-261.	2.6	0
49	Association between pelvic nodal radiotherapy and patient-reported functional outcomes through 5 years among men undergoing external-beam radiotherapy for prostate cancer: An assessment of the comparative effectiveness analysis of surgery and radiation (CEASAR) cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> . 2021, 40, 56.e1-56.e1.	0.8	0
50	B2B: Prostate Cancer. <i>Soci�t� Internationale D'urologie Journal</i> , 2021, 2, S30-S50.	0.2	0
51	Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate Volume. <i>Urology</i> , 2021, , .	0.5	1
52	Understanding the Health Characteristics and Treatment Choices of Older Men with Stress Urinary Incontinence. <i>Urology</i> , 2021, 154, 281-287.	0.5	4
53	Impact of the COVID-19 Pandemic on Urological Care Delivery in the United States. <i>Journal of Urology</i> , 2021, 206, 1469-1479.	0.2	7
54	Diagnostic Accuracy of ⁶⁸ Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection. <i>JAMA Oncology</i> , 2021, 7, 1635.	3.4	138

#	ARTICLE	IF	CITATIONS
55	Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 136-143.	2.0	36
56	Understanding the Major Factors Affecting Response Shift Effects on Health-Related Quality of Life: What the Then-Test Measures in a Longitudinal Prostate Cancer Registry. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e21-e27.	0.9	4
57	Development and pilot evaluation of a personalized decision support intervention for low risk prostate cancer patients. <i>Cancer Medicine</i> , 2020, 9, 125-132.	1.3	7
58	Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts. <i>Cancer</i> , 2020, 126, 583-592.	2.0	9
59	Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized Study. <i>European Urology</i> , 2020, 77, 563-572.	0.9	16
60	The Relative Impact of Urinary and Sexual Function vs Bother on Health Utility for Men With Prostate Cancer. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa044.	1.4	0
61	Evaluation of the 4K score and MRI for the detection of high-grade prostate cancer. <i>European Urology Open Science</i> , 2020, 19, e172-e173.	0.2	0
62	The Evolution of Our Understanding of the Biology of Cancer Is the Key to Avoiding Overdiagnosis and Overtreatment. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2463-2474.	1.1	10
63	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. <i>JCO Precision Oncology</i> , 2020, 4, 1228-1238.	1.5	2
64	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. <i>JAMA Oncology</i> , 2020, 6, 1912.	3.4	49
65	Significant Management Variability of Urethral stricture Disease in United States: Data from the AUA Quality (AQUA) Registry. <i>Urology</i> , 2020, 146, 265-270.	0.5	4
66	Obese men undergoing radical prostatectomy: Is robotic or retropubic better to limit positive surgical margins? Results from SEARCH. <i>International Journal of Urology</i> , 2020, 27, 851-857.	0.5	6
67	Radiotherapy after radical prostatectomy: Effect of timing of postprostatectomy radiation on functional outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 930.e23-930.e32.	0.8	6
68	Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. <i>JAMA Oncology</i> , 2020, 6, e203187.	3.4	30
69	683P Correlation between castration resistant prostate cancer (CRPC) free survival (CRPC-FS) and metastasis free survival (MFS) in men initiating androgen deprivation therapy (ADT) for biochemical recurrence (BCR) after radical prostatectomy (RP): Results from the SEARCH database. <i>Annals of Oncology</i> , 2020, 31, S543.	0.6	0
70	Race does not predict skeletal-related events and all-cause mortality in men with castration-resistant prostate cancer. <i>Cancer</i> , 2020, 126, 3274-3280.	2.0	3
71	Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. <i>European Urology</i> , 2020, 78, 304-306.	0.9	44
72	Expression of ACE2, the SARS-CoV-2 Receptor, and TMPRSS2 in Prostate Epithelial Cells. <i>European Urology</i> , 2020, 78, 296-298.	0.9	110

#	ARTICLE	IF	CITATIONS
73	Obesity, race, and long-term prostate cancer outcomes. <i>Cancer</i> , 2020, 126, 3733-3741.	2.0	32
74	Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data. <i>Cancer</i> , 2020, 126, 2935-2937.	2.0	0
75	Multiparametric Magnetic Resonance Imaging Alone is Insufficient to Detect Grade Reclassification in Active Surveillance for Prostate Cancer. <i>European Urology</i> , 2020, 78, 515-517.	0.9	12
76	Reply to Roderick C.N. van den Bergh, Olivier Rouvière, and Theodoros van der Kwast's Letter to the Editor re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. <i>Eur Urol</i> 2020;78:304-6. Prebiopsy MRI: Through the Looking Glass. <i>European Urology</i> , 2020, 78, 314-315.	0.9	3
77	Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 517-526.	2.0	80
78	Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). <i>European Urology</i> , 2020, 77, 713-724.	0.9	108
79	Development and Internal Validation of a Web-based Tool to Predict Sexual, Urinary, and Bowel Function Longitudinally After Radiation Therapy, Surgery, or Observation. <i>European Urology</i> , 2020, 78, 248-255.	0.9	12
80	The New Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting Database: Opportunities and Limitations. <i>European Urology</i> , 2020, 78, 335-344.	0.9	28
81	Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 149.	3.8	172
82	Active Surveillance for Prostate Cancer: A 2020 Vision. <i>European Urology</i> , 2020, 77, 687-688.	0.9	2
83	Traditional and Virtual Congress Meetings During the COVID-19 Pandemic and the Post-COVID-19 Era: Is it Time to Change the Paradigm?. <i>European Urology</i> , 2020, 78, 301-303.	0.9	100
84	Intermediate-risk Prostate Cancer: Stratification and Management. <i>European Urology Oncology</i> , 2020, 3, 270-280.	2.6	51
85	Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US. <i>JAMA Network Open</i> , 2020, 3, e2031349.	2.8	41
86	Natural language processing systems for pathology parsing in limited data environments with uncertainty estimation. <i>JAMIA Open</i> , 2020, 3, 431-438.	1.0	10
87	Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database. <i>Journal of Urology</i> , 2020, 203, 120-127.	0.2	3
88	Racial Discrepancies in Overall Survival among Men Treated with ²²³ Radium. <i>Journal of Urology</i> , 2020, 203, 331-337.	0.2	25
89	African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study. <i>Journal of Urology</i> , 2020, 203, 727-733.	0.2	30
90	Competing Risks of Mortality among Men with Biochemical Recurrence after Radical Prostatectomy. <i>Journal of Urology</i> , 2020, 204, 511-517.	0.2	9

#	ARTICLE	IF	CITATIONS
91	Magnetic Resonance Imaging for the Detection of High Grade Cancer in the Canary Prostate Active Surveillance Study. <i>Journal of Urology</i> , 2020, 204, 701-706.	0.2	19
92	Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer. <i>Journal of Urology</i> , 2020, 204, 1216-1221.	0.2	9
93	18-year prostate cancer-specific mortality after prostatectomy, brachytherapy, external beam radiation therapy, hormonal therapy, or monitoring for localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 300-300.	0.8	0
94	Abstract D084: Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC)â€”final PROCEED analysis. , 2020, , .		0
95	Abstract D124: Racial differences in adverse pathology among men with prostate cancer at time of radical prostatectomy. , 2020, , .		0
96	Assessing the Quality of Surgical Care for Clinically Localized Prostate Cancer: Results from the CEASAR Study. <i>Journal of Urology</i> , 2020, 204, 1236-1241.	0.2	6
97	Reply by Authors. <i>Journal of Urology</i> , 2020, 204, 1221-1221.	0.2	0
98	Reply by Authors. <i>Journal of Urology</i> , 2020, 203, 127-127.	0.2	0
99	Natural history of an immediately detectable PSA following radical prostatectomy: A description of a contemporary cohort.. <i>Journal of Clinical Oncology</i> , 2020, 38, 356-356.	0.8	1
100	Risk factors which predict biopsy upgrading over time in active surveillance for prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 290-290.	0.8	0
101	Report of the third Asian Prostate Cancerâ€”study meeting. <i>Prostate International</i> , 2019, 7, 60-67.	1.2	4
102	Predictors of skeletalâ€”related events and mortality in men with metastatic, castrationâ€”resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. <i>Cancer</i> , 2019, 125, 4003-4010.	2.0	15
103	Robust Health Utility Assessment Among Long-term Survivors of Prostate Cancer: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor Registry. <i>European Urology</i> , 2019, 76, 743-751.	0.9	5
104	Salvage Radiotherapy for Recurrent Prostate Cancer: Can the Prognostic Grade Group System Inform Treatment Timing?. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e930-e938.	0.9	1
105	Validity of the National Death Index to ascertain the date and cause of death in men having undergone prostatectomy for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 633-635.	2.0	13
106	Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 685-690.	2.6	21
107	Realâ€”world outcomes of sipuleucelâ€”T treatment in PROCEED, a prospective registry of men with metastatic castrationâ€”resistant prostate cancer. <i>Cancer</i> , 2019, 125, 4172-4180.	2.0	49
108	Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 438-445.	2.0	22

#	ARTICLE	IF	CITATIONS
109	Socioeconomic status, race, and long-term outcomes after radical prostatectomy in an equal access health system: Results from the SEARCH database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 289.e11-289.e17.	0.8	16
110	Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project. <i>World Journal of Urology</i> , 2019, 37, 2147-2153.	1.2	32
111	First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH. <i>Cancer Causes and Control</i> , 2019, 30, 259-269.	0.8	3
112	Association of Black Race With Prostate Cancer–Specific and Other-Cause Mortality. <i>JAMA Oncology</i> , 2019, 5, 975.	3.4	288
113	Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 778-789.	0.4	247
114	Trends and Predictors of Adjuvant Therapy for Adverse Features Following Radical Prostatectomy: An Analysis From Cancer of the Prostate Strategic Urologic Research Endeavor. <i>Urology</i> , 2019, 131, 157-165.	0.5	7
115	The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. <i>European Urology</i> , 2019, 76, 268-272.	0.9	28
116	Influence of African American race on the association between preoperative biopsy grade group and adverse histopathologic features of radical prostatectomy. <i>Cancer</i> , 2019, 125, 3025-3032.	2.0	3
117	Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database. <i>Cancer</i> , 2019, 125, 2861-2867.	2.0	20
118	High-throughput, Efficient, and Unbiased Capture of Small RNAs from Low-input Samples for Sequencing. <i>Scientific Reports</i> , 2019, 9, 2262.	1.6	18
119	Practice patterns and outcomes of equivocal bone scans for patients with castration-resistant prostate cancer: Results from SEARCH. <i>Asian Journal of Urology</i> , 2019, 6, 242-248.	0.5	3
120	Obesity at Diagnosis and Prostate Cancer Prognosis and Recurrence Risk Following Primary Treatment by Radical Prostatectomy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1917-1925.	1.1	20
121	Active surveillance for intermediate-risk prostate cancer. <i>Current Opinion in Urology</i> , 2019, 29, 605-611.	0.9	12
122	Automating the Capture of Structured Pathology Data for Prostate Cancer Clinical Care and Research. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-8.	1.0	17
123	Practice patterns of primary EBRT with and without ADT in prostate cancer treatment. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 117-124.	2.0	9
124	Health Care Delivery for Metastatic Hormone-sensitive Prostate Cancer Across the Globe. <i>European Urology Focus</i> , 2019, 5, 155-158.	1.6	13
125	Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?. <i>Cancer</i> , 2019, 125, 434-441.	2.0	3
126	Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 910-916.	2.8	35

#	ARTICLE	IF	CITATIONS
127	Feasibility, Acceptability, and Behavioral Outcomes from a Technology-enhanced Behavioral Change Intervention (Prostate 8): A Pilot Randomized Controlled Trial in Men with Prostate Cancer. <i>European Urology</i> , 2019, 75, 950-958.	0.9	45
128	Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. <i>BJU International</i> , 2019, 124, 69-75.	1.3	15
129	Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e140-e149.	0.9	7
130	PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics. <i>World Journal of Urology</i> , 2019, 37, 1255-1261.	1.2	37
131	The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. <i>Journal of the National Cancer Institute</i> , 2019, 111, 301-310.	3.0	142
132	Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 252-260.	2.0	24
133	Genomic Prostate Score, PI-RADS [®] version 2 and Progression in Men with Prostate Cancer on Active Surveillance. <i>Journal of Urology</i> , 2019, 201, 300-307.	0.2	36
134	Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance. <i>Journal of Urology</i> , 2019, 202, 506-510.	0.2	22
135	Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer. <i>Journal of Urology</i> , 2019, 202, 696-701.	0.2	16
136	A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance. <i>Journal of Urology</i> , 2019, 202, 702-709.	0.2	35
137	Interpretation of Domain Scores on the EPIC [®] "How Does the Domain Score Translate into Functional Outcomes?". <i>Journal of Urology</i> , 2019, 202, 1150-1158.	0.2	11
138	Identification and Characterization of Circulating Tumor Cells in Men Who have Undergone Prostatectomy for Clinically Localized, High Risk Prostate Cancer. <i>Journal of Urology</i> , 2019, 202, 732-741.	0.2	8
139	Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5035-5035.	0.8	6
140	Complex biologic heterogeneity of de novo hormone naïve metastatic prostate cancer (HNPCa): Comparison of early progressors and prolonged responders to initial systemic treatment.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5055-5055.	0.8	1
141	Prostate cancer screening in low- and middle- income countries: the Mexican case. <i>Salud Publica De Mexico</i> , 2019, 61, 542.	0.1	9
142	Racial disparities in radium-223 treatment in a large real-world population.. <i>Journal of Clinical Oncology</i> , 2019, 37, 268-268.	0.8	1
143	Cribiform pattern, Genomic Prostate Score, and adverse pathology at radical prostatectomy in a cohort of prostate cancer patients initially on active surveillance.. <i>Journal of Clinical Oncology</i> , 2019, 37, 88-88.	0.8	0
144	A 17-gene genomic prostate score as a predictor of adverse pathology for men on active surveillance.. <i>Journal of Clinical Oncology</i> , 2019, 37, 97-97.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Radium-223 treatment patterns in a large real-world population.. Journal of Clinical Oncology, 2019, 37, 190-190.	0.8	0
146	A multibiomarker approach to predict prostate cancer pathology outcomes.. Journal of Clinical Oncology, 2019, 37, 58-58.	0.8	1
147	Radical prostatectomy and the effect of close surgical margins: results from the Shared Equal Access Regional Cancer Hospital (<scp>SEARCH</scp>) database. BJU International, 2018, 122, 592-598.	1.3	9
148	Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results. European Urology, 2018, 74, 26-33.	0.9	30
149	Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes and Control, 2018, 29, 581-588.	0.8	30
150	The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration. Journal of Urology, 2018, 200, 541-548.	0.2	11
151	Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. European Urology, 2018, 74, 211-217.	0.9	30
152	First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 239.e17-239.e25.	0.8	12
153	The Effect of Nerve Sparing Status on Sexual and Urinary Function: 3-Year Results from the CEASAR Study. Journal of Urology, 2018, 199, 1202-1209.	0.2	49
154	How Should a Man with Prostate Cancer Choose his Surgeon?. European Urology, 2018, 73, 826-827.	0.9	0
155	Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU International, 2018, 122, 76-82.	1.3	15
156	Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. European Urology, 2018, 73, 168-175.	0.9	53
157	Community-based Outcomes of Open versus Robot-assisted Radical Prostatectomy. European Urology, 2018, 73, 215-223.	0.9	45
158	A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. European Urology, 2018, 73, 156-165.	0.9	55
159	Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group. Journal of Urology, 2018, 199, 713-718.	0.2	7
160	Validation of GEMCaP as a DNA Based Biomarker to Predict Prostate Cancer Recurrence after Radical Prostatectomy. Journal of Urology, 2018, 199, 719-725.	0.2	4
161	Patient Reported Comparative Effectiveness of Contemporary Intensity Modulated Radiation Therapy Versus External Beam Radiation Therapy of the Mid 1990s for Localized Prostate Cancer. Urology Practice, 2018, 5, 471-479.	0.2	1
162	The use of PET/CT in prostate cancer. Prostate Cancer and Prostatic Diseases, 2018, 21, 4-21.	2.0	70

#	ARTICLE	IF	CITATIONS
163	Re: Follow-up of Prostatectomy Versus Observation for Early Prostate Cancer. <i>European Urology</i> , 2018, 73, 477-478.	0.9	0
164	Genomic Markers in Prostate Cancer Decision Making. <i>European Urology</i> , 2018, 73, 572-582.	0.9	201
165	Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?. <i>Journal of Clinical Oncology</i> , 2018, 36, 937-941.	0.8	7
166	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. <i>Journal of Clinical Oncology</i> , 2018, 36, 414-424.	0.8	155
167	Genomic biomarkers in prostate cancer. <i>Translational Andrology and Urology</i> , 2018, 7, 459-471.	0.6	46
168	Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital. <i>International Journal of Urology</i> , 2018, 25, 998-1004.	0.5	13
169	Estimating and comparing cancer progression risks under varying surveillance protocols. <i>Annals of Applied Statistics</i> , 2018, 12, 1773-1795.	0.5	8
170	Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy. <i>European Urology</i> , 2018, 74, 668-675.	0.9	34
171	Prostate Cancer Markers. <i>Cancer Treatment and Research</i> , 2018, 175, 55-86.	0.2	10
172	Contemporary prostate cancer radiation therapy in the United States: Patterns of care and compliance with quality measures. <i>Practical Radiation Oncology</i> , 2018, 8, 307-316.	1.1	12
173	Online Professionalism—2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. <i>European Urology</i> , 2018, 74, 644-650.	0.9	53
174	A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. <i>European Urology</i> , 2018, 74, 197-203.	0.9	93
175	The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer. <i>European Urology</i> , 2018, 74, 444-452.	0.9	55
176	Measuring quality of urology care using a qualified clinical data registry. <i>Current Opinion in Urology</i> , 2018, 28, 329-335.	0.9	3
177	Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer. <i>European Urology Oncology</i> , 2018, 1, 386-394.	2.6	32
178	Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. <i>Annals of Internal Medicine</i> , 2018, 168, 1.	2.0	33
179	Comparison of Patient-reported Outcomes After External Beam Radiation Therapy and Combined External Beam With Low-dose-rate Brachytherapy Boost in Men With Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 116-126.	0.4	11
180	Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. <i>European Urology Oncology</i> , 2018, 1, 78-82.	2.6	74

#	ARTICLE	IF	CITATIONS
181	Cerebrovascular event (CVE) outcome and overall survival (OS) in patients (pts) treated with sipuleucel-T (sip-T) for metastatic castration-resistant prostate cancer (mCRPC): results from the PROCEED registry.. Journal of Clinical Oncology, 2018, 36, e17018-e17018.	0.8	1
182	Comparison of a low-cost immunohistochemistry marker panel with a cell-cycle progression assay for the prediction of outcome after radical prostatectomy.. Journal of Clinical Oncology, 2018, 36, 118-118.	0.8	2
183	Identification and characterization of circulating tumor cells in post prostatectomy patients with localized high risk prostate cancer.. Journal of Clinical Oncology, 2018, 36, 69-69.	0.8	3
184	Active Surveillance in African-Americans. , 2018, , 53-58.		0
185	When can active surveillance be less active? Prediction of long-term nonreclassification for men with low-risk prostate cancer.. Journal of Clinical Oncology, 2018, 36, 140-140.	0.8	0
186	Prostate 8 study: A pilot randomized controlled trial (RCT) of a web-based lifestyle intervention versus control group among men with prostate cancer.. Journal of Clinical Oncology, 2018, 36, 105-105.	0.8	0
187	The diverse genomic landscape of lowârisk prostate cancer.. Journal of Clinical Oncology, 2018, 36, 74-74.	0.8	0
188	Development and pilot testing of a decision support intervention for men with prostate cancer.. Journal of Clinical Oncology, 2018, 36, 132-132.	0.8	0
189	Sipuleucel-T (sip-T) overall survival (OS) and clinical outcomes by baseline (BL) prostate-specific antigen (PSA) quartiles in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROCEED registry.. Journal of Clinical Oncology, 2018, 36, 5041-5041.	0.8	0
190	Quantified Clinical Risk Change as an End Point During Prostate Cancer Active Surveillance. European Urology, 2017, 72, 329-332.	0.9	8
191	Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, e299-e309.	0.9	25
192	Report of the Second Asian Prostate Cancer (A-CaP) Study Meeting. Prostate International, 2017, 5, 95-103.	1.2	7
193	Declining Incidence Rates of Prostate Cancer in the United States. JAMA Oncology, 2017, 3, 1623.	3.4	10
194	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncology, 2017, 3, 1663.	3.4	219
195	MP69-07 HASHTAG PEER-REVIEW: DOES EARLY SOCIAL MEDIA SUCCESS CORRELATE WITH CONVENTIONAL METRICS OF PUBLICATION IMPACT?. Journal of Urology, 2017, 197, .	0.2	2
196	Epidemiology of prostate cancer. World Journal of Urology, 2017, 35, 849-849.	1.2	24
197	Impact of the United States Preventive Services Task Force âDâ™ recommendation on prostate cancer screening and staging. Current Opinion in Urology, 2017, 27, 205-209.	0.9	45
198	Tissue Sources for Accurate Measurement of Germline DNA Genotypes in Prostate Cancer Patients Treated With Radical Prostatectomy. Prostate, 2017, 77, 425-434.	1.2	4

#	ARTICLE	IF	CITATIONS
199	Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. <i>European Urology</i> , 2017, 72, 448-454.	0.9	61
200	Impact of ⁶⁸ Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1956-1961.	2.8	111
201	The New US Preventive Services Task Force "C" Draft Recommendation for Prostate Cancer Screening. <i>European Urology</i> , 2017, 72, 326-328.	0.9	2
202	Characterization of a "low-risk" cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database. <i>International Journal of Urology</i> , 2017, 24, 611-617.	0.5	3
203	The Influence of Psychosocial Constructs on the Adherence to Active Surveillance for Localized Prostate Cancer in a Prospective, Population-based Cohort. <i>Urology</i> , 2017, 103, 173-178.	0.5	18
204	Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2017, 120, E80-E86.	1.3	46
205	MP93-08 INTERPRETING PATIENT-REPORTED URINARY AND SEXUAL FUNCTION OUTCOMES ACROSS MULTIPLE VALIDATED INSTRUMENTS. <i>Journal of Urology</i> , 2017, 197, .	0.2	3
206	Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1126.	3.8	261
207	Interpreting Patient Reported Urinary and Sexual Function Outcomes across Multiple Validated Instruments. <i>Journal of Urology</i> , 2017, 198, 671-677.	0.2	16
208	Clinically localized prostate cancer in 2017: A review of comparative effectiveness. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 40-41.	0.8	20
209	Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2017, 123, 1528-1535.	2.0	22
210	Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes. <i>European Urology</i> , 2017, 71, 750-759.	0.9	40
211	Whom to Treat. <i>Urologic Clinics of North America</i> , 2017, 44, 547-555.	0.8	5
212	Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH. <i>Prostate</i> , 2017, 77, 1592-1600.	1.2	8
213	Outcomes of men on active surveillance for low-risk prostate cancer at a safety-net hospital. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 663.e9-663.e14.	0.8	10
214	The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy. <i>Cancer</i> , 2017, 123, 4574-4582.	2.0	36
215	PD40-07 DOES EARLY PSADT (EPSADT) AFTER RADICAL PROSTATECTOMY, CALCULATED PRIOR TO PSA RECURRENCE, CORRELATE WITH PROSTATE CANCER (PC) OUTCOMES? RESULTS FROM THE SEARCH DATABASE. <i>Journal of Urology</i> , 2017, 197, .	0.2	1
216	PD71-05 VALIDATION OF GEMCAP AS A DNA BASED BIOMARKER TO PREDICT PROSTATE CANCER RECURRENCE AFTER RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2017, 197, .	0.2	0

#	ARTICLE	IF	CITATIONS
217	PNFBA-07 THE CURRENT MANAGEMENT OF PROSTATE CANCER IN THE UNITED STATES: DATA FROM THE AQUA REGISTRY. <i>Journal of Urology</i> , 2017, 197, .	0.2	7
218	PD10-11 ANALYSIS OF THE PREDICTIVE UTILITY OF PROGNOSTIC GRADE GROUPS (PGG) FOR PREDICTING PERIOPERATIVE ONCOLOGIC OUTCOMES OF RADICAL PROSTATECTOMY IN THE SHARED EQUAL ACCESS REGIONAL CANCER HOSPITAL (SEARCH) DATABASE. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
219	Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence. <i>Urology</i> , 2017, 108, 129-134.	0.5	17
220	PD40-12 DO SICKER PEOPLE HAVE WORSE PROSTATE CANCER-SPECIFIC OUTCOMES AFTER RADICAL PROSTATECTOMY? RESULTS FROM SEARCH. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
221	MP64-09 THE IMPACT OF LYMPH NODES COUNT AND ADJUVANT THERAPY ON ONCOLOGIC OUTCOMES IN MEN WITH LYMPH NODE METASTASIS AT THE TIME OF RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
222	PNFBA-09 THE DIVERSE GENOMIC LANDSCAPE OF LOW-RISK PROSTATE CANCER. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
223	PD15-05 REAL-WORLD OUTCOMES OF OPEN VERSUS ROBOT-ASSISTED RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
224	MP14-02 THE NATURAL HISTORY OF MEN ON ACTIVE SURVEILLANCE WITH LOW-RISK PROSTATE CANCER AT A SAFETY-NET, COUNTY HOSPITAL. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
225	PD10-09 EFFECT OF DEHYDRATED HUMAN AMNION/CHORION MEMBRANE ALLOGRAFT ON URINARY CONTINENCE FOLLOWING ROBOT-ASSISTED RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2017, 197, .	0.2	1
226	MP20-02 NOVEL RISK STRATIFICATION GROUPING USING STANDARD CLINICAL AND BIOPSY INFORMATION FOR PATIENTS UNDERGOING RADICAL PROSTATECTOMY: RESULTS FROM SEARCH. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
227	MP20-19 WHAT ARE THE BEST CUT-POINTS FOR PSA DOUBLING TIME IN MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER?. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
228	Predictors of operative time during radical retropubic prostatectomy and robot-assisted laparoscopic prostatectomy. <i>International Journal of Urology</i> , 2017, 24, 618-623.	0.5	16
229	PD47-10 THE RESEARCH IMPLICATIONS OF PSA REGISTRY ERRORS. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
230	PD24-09 IN MEN WITH CASTRATION-RESISTANT PROSTATE CANCER VISCERAL METASTASES PREDICTS SHORTER OVERALL SURVIVAL: WHAT PREDICTS VISCERAL METASTASES? RESULTS FROM THE SEARCH DATABASE. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
231	PD24-12 OVERALL SURVIVAL ANALYSIS OF AFRICAN AMERICAN AND CAUCASIAN PATIENTS RECEIVING SIPULEUCEL-T: PRELIMINARY DATA FROM THE PROCEED REGISTRY. <i>Journal of Urology</i> , 2017, 197, .	0.2	2
232	PD28-04 THE INFLUENCE OF PSYCHOSOCIAL CONSTRUCTS ON THE ADHERENCE TO ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER IN A PROSPECTIVE, POPULATION-BASED COHORT. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
233	PD28-12 EFFECTS OF INITIAL GLEASON GRADE ON OUTCOMES DURING ACTIVE SURVEILLANCE FOR PROSTATE CANCER. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
234	MP43-11 REFINED ANALYSIS OF PROSTATE SPECIFIC ANTIGEN (PSA) VELOCITY TO PREDICT OUTCOMES IN ACTIVE SURVEILLANCE: RESULTS FROM THE CANARY PROSTATE ACTIVE SURVEILLANCE STUDY (PASS). <i>Journal of Urology</i> , 2017, 197, .	0.2	0

#	ARTICLE	IF	CITATIONS
235	MP47-09 TIMING OF PSA NADIR AFTER RADICAL PROSTATECTOMY AND RISK OF BIOCHEMICAL RECURRENCE: DOES IT MATTER? RESULTS FROM THE SEARCH DATABASE. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
236	PD03-08 IMPACT OF AGE, COMORBIDITY, AND PSA DOUBLING TIME ON LONG-TERM COMPETING RISKS FOR MORTALITY AMONG MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
237	PD03-10 VALIDATION OF THE 2015 PROSTATE CANCER PROGNOSTIC GRADE GROUPS FOR PREDICTING LONG-TERM ONCOLOGIC OUTCOMES IN A SHARED EQUAL ACCESS HEALTH SYSTEM.. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
238	MP96-10 INITIAL VALIDATION OF AUTOMATED DATA EXTRACTION METHODS IN UROLOGIC ONCOLOGY PRACTICE. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
239	MP20-09 EVALUATING MRI FUSION BIOPSY VS SYSTEMATIC ULTRASOUND GUIDED BIOPSY IN PREDICTING HIGH GRADE CANCER AT TIME OF RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
240	PD18-08 PROSPECTIVE MULTICENTER COMPARISON OF OPEN AND ROBOTIC RADICAL PROSTATECTOMY: THE PROST-QA/RP2 CONSORTIUM. <i>Journal of Urology</i> , 2017, 197, .	0.2	1
241	Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer. <i>Journal of Urology</i> , 2017, 198, 1309-1315.	0.2	15
242	Re: Association between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes after 3 Years. <i>Journal of Urology</i> , 2017, 198, 743-744.	0.2	0
243	Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database. <i>Cancer</i> , 2017, 123, 4199-4206.	2.0	30
244	Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system. <i>Cancer</i> , 2017, 123, 4122-4129.	2.0	15
245	What Early ProtecT Results Have Confirmed About Risk-stratified Prostate Cancer Management. <i>European Urology</i> , 2017, 71, 389-390.	0.9	1
246	Re: 10-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. <i>European Urology</i> , 2017, 71, 492-493.	0.9	2
247	Magnetic Resonance Imaging-targeted Prostate Biopsies: Is the Right Technique the Right Question?. <i>European Urology</i> , 2017, 71, 532-533.	0.9	4
248	Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 72-78.	2.0	41
249	Active Surveillance for Low-Risk Prostate Cancer-An Evolving International Standard of Care. <i>JAMA Oncology</i> , 2017, 3, 1398.	3.4	19
250	Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database. <i>Prostate</i> , 2017, 77, 154-163.	1.2	22
251	Racial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Results from the CEASAR Study. <i>European Urology</i> , 2017, 72, 307-314.	0.9	19
252	Validity of the Cancer of the Prostate Risk Assessment Score Derived From Targeted Biopsy: Modeling Evidence From Ultrasound Lesion-Directed Biopsy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 93-99.	0.9	1

#	ARTICLE	IF	CITATIONS
253	Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer. <i>European Urology</i> , 2017, 71, 729-737.	0.9	110
254	In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database. <i>European Urology Focus</i> , 2017, 3, 480-486.	1.6	11
255	The AUA Quality Registry: Engaging Stakeholders to Improve the Quality of Care for Patients with Prostate Cancer. <i>Urology Practice</i> , 2017, 4, 30-35.	0.2	20
256	A Randomized Study of Intraoperative Autologous Retropubic Urethral Sling on Urinary Control after Robotic Assisted Radical Prostatectomy. <i>Journal of Urology</i> , 2017, 197, 369-375.	0.2	19
257	Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 60-66.e2.	0.9	79
258	The CAPRA Score at 10 Years: Contemporary Perspectives and Analysis of Supporting Studies. <i>European Urology</i> , 2017, 71, 705-709.	0.9	72
259	Clinical risk stratification for prostate cancer: Where are we, and where do we need to go?. <i>Canadian Urological Association Journal</i> , 2017, 11, 101.	0.3	5
260	Active Surveillance in Younger Men With Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 1898-1904.	0.8	46
261	Incidence of intrathoracic (IT) metastases detected by 68Ga-PSMA-11 PET in early stage prostate cancer (PC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5056-5056.	0.8	1
262	Luminal and basal subtyping of prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3-3.	0.8	2
263	The diverse genomic landscape of low-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 72-72.	0.8	2
264	Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa). <i>PLoS ONE</i> , 2017, 12, e0185535.	1.1	22
265	Luminal and basal subtyping of prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 2017, 3-3.	0.8	0
266	Characterization of circulating tumor cells in patients with localized high risk prostate cancer, post-prostatectomy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 110-110.	0.8	0
267	Validation of GEMCaP as a DNA based biomarker to predict disease recurrence in patients undergoing prostatectomy for prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 58-58.	0.8	0
268	Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5057-5057.	0.8	0
269	Evaluation of microarrays for measuring cell cycle progression (CCP) gene expression.. <i>Journal of Clinical Oncology</i> , 2017, 35, e16566-e16566.	0.8	0
270	A randomized study of enzalutamide in patients with localized prostate cancer undergoing active surveillance (ENACT).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5097-TPS5097.	0.8	0

#	ARTICLE	IF	CITATIONS
271	Characterization of circulating tumor cells in patients with localized high risk prostate cancer, post-prostatectomy.. Journal of Clinical Oncology, 2017, 35, e23055-e23055.	0.8	0
272	Accuracy of Prostate-Specific Antigen Values in Prostate Cancer Registries. Journal of Clinical Oncology, 2016, 34, 3586-3587.	0.8	8
273	Global treatment patterns for late-stage prostate cancer: Updated results from ASPIRE-PCa. Annals of Oncology, 2016, 27, vi253.	0.6	0
274	Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. International Journal of Urology, 2016, 23, 241-246.	0.5	2
275	Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. Journal of Urology, 2016, 196, 1408-1414.	0.2	43
276	Impact of frailty on complications in patients undergoing common urological procedures: a study from the American College of Surgeons National Surgical Quality Improvement database. BJU International, 2016, 117, 836-842.	1.3	111
277	Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database. Cancer, 2016, 122, 222-229.	2.0	6
278	Validation of a bone scan positivity risk table in non-metastatic castration-resistant prostate cancer. BJU International, 2016, 118, 570-577.	1.3	8
279	Do all men with pathological Gleason score 8-10 prostate cancer have poor outcomes? Results from the SEARCH database. BJU International, 2016, 118, 250-257.	1.3	12
280	Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?. Prostate Cancer and Prostatic Diseases, 2016, 19, 380-384.	2.0	40
281	Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted?. BJU International, 2016, 117, 897-903.	1.3	7
282	Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized. American Journal of Surgical Pathology, 2016, 40, 1439-1456.	2.1	107
283	Clinical Utility of Biomarkers in Localized Prostate Cancer. Current Oncology Reports, 2016, 18, 30.	1.8	13
284	MP31-08 PREOPERATIVE FRAILTY IS ASSOCIATED WITH DISCHARGE TO SKILLED OR ASSISTED LIVING FACILITIES AFTER UROLOGY PROCEDURES OF VARYING COMPLEXITY. Journal of Urology, 2016, 195, .	0.2	0
285	PD42-03 PATHOLOGIC AND BIOCHEMICAL OUTCOMES AMONG AFRICAN-AMERICAN AND CAUCASIAN MEN WITH LOW-RISK PROSTATE CANCER IN THE SEARCH DATABASE: IMPLICATIONS FOR ACTIVE SURVEILLANCE CANDIDACY. Journal of Urology, 2016, 195, .	0.2	0
286	MP79-15 RADICAL PROSTATECTOMY AND THE EFFECT OF CLOSE SURGICAL MARGINS: ANALYSIS FROM THE SEARCH DATABASE. Journal of Urology, 2016, 195, .	0.2	0
287	PD28-05 FACTORS PREDICTING SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. Journal of Urology, 2016, 195, .	0.2	0
288	MP09-18 BIOPSY-DETECTED GLEASON PATTERN 5 IS A PARTICULARLY STRONG PREOPERATIVE PREDICTOR OF RECURRENCE, METASTASIS, AND MORTALITY IN MEN WITH HIGH-RISK PROSTATE CANCER. Journal of Urology, 2016, 195, .	0.2	0

#	ARTICLE	IF	CITATIONS
289	PD43-02 ARE WE OPERATING ON WHO WE SHOULD? THE CHANGING CHARACTERISTICS OF RADICAL PROSTATECTOMY PATIENTS: RESULTS FROM THE SHARED EQUAL ACCESS REGIONAL CANCER HOSPITAL (SEARCH) DATABASE. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
290	PD02-01 THE IMPACT OF FRAILTY ON COMPLICATIONS IN PATIENTS UNDERGOING COMMON UROLOGIC PROCEDURES; A STUDY FROM THE AMERICAN COLLEGE OF SURGEONS NATIONAL SURGICAL QUALITY IMPROVEMENT DATABASE. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
291	PD03-01 YOUNGER AGE IS ASSOCIATED WITH DECREASED RISK OF BIOPSY PROGRESSION DURING ACTIVE SURVEILLANCE FOR LOW AND INTERMEDIATE RISK PROSTATE CANCER. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
292	Racial Differences in the Association Between Preoperative Serum Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH Database. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 547-554.	1.1	15
293	MP80-01 PHOSPHODIESTERASE TYPE 5 INHIBITOR USE IS NOT ASSOCIATED WITH BIOCHEMICAL RECURRENCE AFTER DEFINITIVE THERAPY FOR PROSTATE CANCER. <i>Journal of Urology</i> , 2016, 195, .	0.2	1
294	S&T-12 RACE DOES NOT PREDICT THE DEVELOPMENT OF METASTASES IN MEN WITH NON-METASTATIC CASTRATE RESISTANT PROSTATE CANCER. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
295	When to Start Prostate Cancer Screening and When to Stop: Insights from Gärtteborg. <i>Journal of Urology</i> , 2016, 195, 1325-1326.	0.2	1
296	Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. <i>Cancer Immunology Research</i> , 2016, 4, 948-958.	1.6	26
297	Identification and Validation of Intrinsic Subtypes of Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, S3-S4.	0.4	2
298	Long-term oncological outcomes of apical positive surgical margins at radical prostatectomy in the Shared Equal Access Regional Cancer Hospital cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 423-428.	2.0	22
299	An Approach Using PSA Levels of 1.5â€‰ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. <i>Urology</i> , 2016, 96, 116-120.	0.5	11
300	Race does not predict the development of metastases in men with nonmetastatic castrationâ€resistant prostate cancer. <i>Cancer</i> , 2016, 122, 3848-3855.	2.0	8
301	Targeted PET imaging for prostate-specific membrane antigen in prostate cancer. <i>Future Oncology</i> , 2016, 12, 2393-2396.	1.1	3
302	Transâ€scp>P</scp>acific variation in outcomes for men treated with primary androgenâ€deprivation therapy (<scp>ADT</scp>) for prostate cancer. <i>BJU International</i> , 2016, 117, 102-109.	1.3	57
303	Variation in prostate cancer treatment associated with population density of the county of residence. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 174-179.	2.0	21
304	Preoperative Frailty Is Associated With Discharge to Skilled or Assisted Living Facilities After Urologic Procedures of Varying Complexity. <i>Urology</i> , 2016, 97, 25-32.	0.5	49
305	Why the prostate arm of the PLCO trial failed and what it has taught us. <i>Nature Reviews Urology</i> , 2016, 13, 439-440.	1.9	1
306	Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 1612-1620.	5.1	182

#	ARTICLE	IF	CITATIONS
307	PI-03 A RANDOMIZED STUDY OF INTRA-OPERATIVE AUTOLOGOUS RETROPUBIC URETHRAL SLING ON URINARY CONTROL AFTER ROBOT ASSISTED RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
308	Is Surgery Still Necessary for Prostate Cancer?. , 2016, , 235-243.		0
309	Predictors of Time to Metastasis in Castration-resistant Prostate Cancer. <i>Urology</i> , 2016, 96, 171-176.	0.5	55
310	S&T-25 ANDROGEN DEPRIVATION THERAPY IN THE CONTEXT OF DOSE ESCALATING RADIATION: COMMUNITY PRACTICE PATTERNS AND OUTCOMES. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
311	Asia prostate cancer study (A-CaP Study) launch symposium. <i>Prostate International</i> , 2016, 4, 88-96.	1.2	7
312	PD17-11 THE GLOBAL BURDEN OF GENITOURINARY CANCER: GEOGRAPHIC AND TEMPORAL TRENDS IN MORBIDITY AND MORTALITY. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
313	MP50-13 VALIDATION OF A BONE SCAN POSITIVITY RISK TABLE IN NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
314	Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (<scp>SEARCH</scp>) cohort. <i>BJU International</i> , 2016, 117, 244-248.	1.3	20
315	Prostate Cancer Registries: Current Status and Future Directions. <i>European Urology</i> , 2016, 69, 998-1012.	0.9	56
316	Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. <i>European Urology</i> , 2016, 69, 775-787.	0.9	72
317	Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma. <i>European Urology</i> , 2016, 69, 374-375.	0.9	0
318	Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies. <i>JAMA Oncology</i> , 2016, 2, 890.	3.4	65
319	Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 395-406.	1.2	46
320	Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 227 T <i>Clinical Oncology</i> , 2016, 34, 2182-2190.	0.8	285
321	Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score. <i>Urology</i> , 2016, 89, 69-75.	0.5	43
322	Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. <i>Journal of Urology</i> , 2016, 195, 313-320.	0.2	122
323	The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples. <i>Journal of Urology</i> , 2016, 195, 321-329.	0.2	50
324	Reply from Authors re: Julia Verne, Luke Hounsome, Roger Kockelbergh, Jem Rashbass. Improving Outcomes from Prostate Cancer: Unlocking the Treasure Trove of Information in Cancer Registries. <i>Eur Urol</i> 2016;69:1013-4. <i>European Urology</i> , 2016, 69, 1015.	0.9	1

#	ARTICLE	IF	CITATIONS
325	A pharmacodynamic study of pre-prostatectomy buparlisib in men with high-risk, localized prostate cancer.. Journal of Clinical Oncology, 2016, 34, e14110-e14110.	0.8	3
326	Relationship of phosphodiesterase type 5 inhibitor to biochemical recurrence after definitive therapy for prostate cancer.. Journal of Clinical Oncology, 2016, 34, 119-119.	0.8	4
327	Analysis of the PROCEED registry by baseline prostate-specific antigen (PSA) quartiles: Preliminary analysis of real-world sipuleucel-T (sip-T) use.. Journal of Clinical Oncology, 2016, 34, 193-193.	0.8	1
328	Real-world experience of therapeutic sequencing and time to first anticancer intervention (ACI) following sipuleucel-T (sip-T): Initial data from the PROCEED registry.. Journal of Clinical Oncology, 2016, 34, 194-194.	0.8	1
329	Patient-specific meta-analysis (MA) of two validation studies to predict pathologic outcomes in prostate cancer (PCa) using a 17-gene genomic prostate score (GPS).. Journal of Clinical Oncology, 2016, 34, 100-100.	0.8	0
330	Changing characteristics of patients treated with sipuleucel-T (sip-T) over time: Real-world experience from the PROCEED registry.. Journal of Clinical Oncology, 2016, 34, 320-320.	0.8	0
331	Change in a 17-gene genomic prostate score over time in men with low- and intermediate-risk prostate cancer managed with active surveillance.. Journal of Clinical Oncology, 2016, 34, 124-124.	0.8	0
332	Pathologic and biochemical outcomes among African American and Caucasian men with low-risk prostate cancer in the search database: Implications for active surveillance candidacy.. Journal of Clinical Oncology, 2016, 34, 76-76.	0.8	0
333	Clinical Risk Prediction Tools for Prostate Cancer: TNM to CAPRAâ€”Should Risk Be Redefined?. , 2016, , 33-52.		0
334	External validation of a prognostic Gleason grade classification system.. Journal of Clinical Oncology, 2016, 34, 123-123.	0.8	0
335	Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) in oncology (ONC) urology (URO) practices: Data from the PROCEED registry.. Journal of Clinical Oncology, 2016, 34, e16503-e16503.	0.8	0
336	Reduction in therapeutic burden from use of CCP test in treatment decisions among newly diagnosed prostate cancer patients independent of Charlson Comorbidity Index.. Journal of Clinical Oncology, 2016, 34, e16572-e16572.	0.8	0
337	Characteristics and anticancer interventions (ACIs) in African American (AA) and Caucasian (CAU) patients (pts) treated with sipuleucel-T (sip-T): Real-world experience from the PROCEED registry.. Journal of Clinical Oncology, 2016, 34, 5025-5025.	0.8	1
338	Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancerâ€”Results from the SEARCH database. Cancer Epidemiology, 2015, 39, 1066-1070.	0.8	0
339	Smoking is a predictor of adverse pathological features at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. International Journal of Urology, 2015, 22, 658-662.	0.5	10
340	Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter?. BJU International, 2015, 116, 713-720.	1.3	13
341	Diagnostic associations of gene expression signatures in prostate cancer tissue. Current Opinion in Urology, 2015, 25, 65-70.	0.9	38
342	Who Bears the Greatest Burden of Aggressive Treatment of Indolent Prostate Cancer?. American Journal of Medicine, 2015, 128, 609-616.	0.6	21

#	ARTICLE	IF	CITATIONS
343	Updated Survey of Social Media Use by Members of the American Urological Association. Urology Practice, 2015, 2, 138-143.	0.2	14
344	The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). Journal of the National Cancer Institute, 2015, 107, djv261.	3.0	53
345	Point: Surgery is the most cost-effective option for prostate cancer needing treatment. Brachytherapy, 2015, 14, 753-755.	0.2	0
346	European Urology: Serving Our Readership Through Systematic Peer Review, Use of Reporting Standards, and Encouragement of Postpublication Review. European Urology, 2015, 67, 188-190.	0.9	0
347	Extended Followup and Risk Factors for Disease Reclassification in a Large Active Surveillance Cohort for Localized Prostate Cancer. Journal of Urology, 2015, 193, 807-811.	0.2	148
348	Proton Therapy Websites: Information Anarchy Creates Confusion. BJU International, 2015, 115, 183-185.	1.3	5
349	Current Use of Imaging after Primary Treatment of Prostate Cancer. Journal of Urology, 2015, 194, 98-104.	0.2	4
350	Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?. Cancer, 2015, 121, 1414-1421.	2.0	12
351	Impact of Age on Quality-of-life Outcomes After Treatment for Localized Prostate Cancer. European Urology, 2015, 68, 480-486.	0.9	42
352	Long-Term Active Surveillance for Prostate Cancer: Answers and Questions. Journal of Clinical Oncology, 2015, 33, 238-240.	0.8	22
353	The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research. European Urology, 2015, 67, 1019-1025.	0.9	15
354	Editorial Comment. Urology, 2015, 85, 1223.	0.5	1
355	Agent Orange and long-term outcomes after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 329.e1-329.e6.	0.8	5
356	Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. JAMA - Journal of the American Medical Association, 2015, 314, 80.	3.8	543
357	Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2015, 18, 333-337.	2.0	27
358	Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project. Prostate Cancer and Prostatic Diseases, 2015, 18, 149-154.	2.0	41
359	Genomic Predictors of Outcome in Prostate Cancer. European Urology, 2015, 68, 1033-1044.	0.9	166
360	Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. European Journal of Cancer, 2015, 51, 817-824.	1.3	56

#	ARTICLE	IF	CITATIONS
361	Long-term Health-related Quality of Life After Primary Treatment for Localized Prostate Cancer: Results from the CaPSURE Registry. <i>European Urology</i> , 2015, 68, 600-608.	0.9	156
362	The Molecular Taxonomy of Primary Prostate Cancer. <i>Cell</i> , 2015, 163, 1011-1025.	13.5	2,435
363	Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. <i>International Journal of Urology</i> , 2015, 22, 362-366.	0.5	12
364	Rebuttal to Drs. Markovina and Michalski. <i>Brachytherapy</i> , 2015, 14, 761-762.	0.2	0
365	Practice Patterns and Predictors of Followup Imaging after a Negative Bone Scan in Men with Castration Resistant Prostate Cancer: Results from the SEARCH Database. <i>Journal of Urology</i> , 2015, 193, 1232-1238.	0.2	11
366	Treatment Trends for Prostate Cancer—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1977.	3.8	2
367	Progress in Management of Low-risk Prostate Cancer: How Registries May Change the World. <i>European Urology</i> , 2015, 67, 51-52.	0.9	8
368	Racial Variation in Prostate Cancer Upgrading and Upstaging Among Men with Low-risk Clinical Characteristics. <i>European Urology</i> , 2015, 67, 451-457.	0.9	78
369	Combined Value of Validated Clinical and Genomic Risk Stratification Tools for Predicting Prostate Cancer Mortality in a High-risk Prostatectomy Cohort. <i>European Urology</i> , 2015, 67, 326-333.	0.9	178
370	RE: Proximal bulbar periurethral abscess. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2015, 41, 186-187.	0.7	0
371	miR-19, miR-345, miR-519c-5p Serum Levels Predict Adverse Pathology in Prostate Cancer Patients Eligible for Active Surveillance. <i>PLoS ONE</i> , 2014, 9, e98597.	1.1	41
372	Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer. <i>BJU International</i> , 2014, 114, E18-E24.	1.3	43
373	Implementation of PSA-based active surveillance in prostate cancer. <i>Biomarkers in Medicine</i> , 2014, 8, 747-753.	0.6	4
374	Updated trends in imaging use in men diagnosed with prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 246-251.	2.0	18
375	Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naïve men and patients receiving androgen-deprivation therapy: results from the SEARCH database. <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 91-96.	2.0	12
376	A Simple Schema for Informed Decision Making About Prostate Cancer Screening. <i>Annals of Internal Medicine</i> , 2014, 161, 441.	2.0	25
377	The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer. <i>Cancer</i> , 2014, 120, 1656-1662.	2.0	24
378	Use of social media in urology: data from the American Urological Association (AUA). <i>BJU International</i> , 2014, 113, 993-998.	1.3	135

#	ARTICLE	IF	CITATIONS
379	Temporal trends and predictors of salvage cancer treatment after failure following radical prostatectomy or radiation therapy: An analysis from the CaPSURE registry. <i>Cancer</i> , 2014, 120, 507-512.	2.0	32
380	Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment. <i>Cancer</i> , 2014, 120, 1263-1271.	2.0	38
381	Meaningful end points and outcomes in men on active surveillance for early-stage prostate cancer. <i>Current Opinion in Urology</i> , 2014, 24, 288-292.	0.9	22
382	Overdetection of Recurrence after Radical Prostatectomy: Estimates Based on Patient and Tumor Characteristics. <i>Clinical Cancer Research</i> , 2014, 20, 5302-5310.	3.2	19
383	Editorial Comment. <i>Journal of Urology</i> , 2014, 192, 80-81.	0.2	0
384	Early Detection of Prostate Cancer. <i>Urologic Clinics of North America</i> , 2014, 41, xiii.	0.8	0
385	The <i>Melbourne Consensus Statement on the early detection of prostate cancer</i> . <i>BJU International</i> , 2014, 113, 186-188.	1.3	64
386	Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the <i>Shered Equal Access Regional Cancer Hospital (SEARCH)</i> database. <i>BJU International</i> , 2014, 114, 661-666.	1.3	46
387	Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy. <i>Cancer</i> , 2014, 120, 197-204.	2.0	69
388	Novel Tools to Improve Patient Selection and Monitoring on Active Surveillance for Low-risk Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2014, 65, 1023-1031.	0.9	118
389	Impact of national guidelines on brachytherapy monotherapy practice patterns for prostate cancer. <i>Cancer</i> , 2014, 120, 824-832.	2.0	4
390	A risk-adjusted definition of biochemical recurrence after radical prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 174-179.	2.0	12
391	Reply to Yuri Tolkach, Markus Kuczyk, Florian Imkamp's Letter to the Editor re: Eric A. Klein, Matthew R. Cooperberg, Cristina Magi-Galluzzi, et al. A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. <i>Eur Urol</i> 2014;66:550-60. <i>European Urology</i> , 2014, 66, e117-e118.	0.9	8
392	National Prostate Cancer Registries: Contemporary Trends of Prostate Cancer in the United States. <i>Urology Practice</i> , 2014, 1, 198-204.	0.2	4
393	Expected population impacts of discontinued prostate-specific antigen screening. <i>Cancer</i> , 2014, 120, 3519-3526.	2.0	90
394	Serum Lipid Profile and Risk of Prostate Cancer Recurrence: Results from the SEARCH Database. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2349-2356.	1.1	111
395	European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. <i>European Urology</i> , 2014, 66, 628-632.	0.9	72
396	Long-term follow-up of International Prostate Symptom Score (IPSS) in men following prostate brachytherapy. <i>World Journal of Urology</i> , 2014, 32, 1061-1066.	1.2	11

#	ARTICLE	IF	CITATIONS
397	Implications of the New AUA Guidelines on Prostate Cancer Detection in the U.S.. Current Urology Reports, 2014, 15, 420.	1.0	19
398	A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. European Urology, 2014, 66, 550-560.	0.9	553
399	A new look at prostate cancer treatment complications. Nature Reviews Clinical Oncology, 2014, 11, 304-305.	12.5	10
400	Impact of Androgen Deprivation Therapy on Mental and Emotional Well-Being in Men with Prostate Cancer: Analysis from the CaPSURE Registry. Journal of Urology, 2014, 191, 964-970.	0.2	36
401	Multi-institutional Validation of the CAPRA-S Score to Predict Disease Recurrence and Mortality After Radical Prostatectomy. European Urology, 2014, 65, 1171-1177.	0.9	110
402	Seventh Joint Meeting of KJ-CaP and CaPSURE: extending the global initiative to improve prostate cancer management. Prostate International, 2014, 2, 50-69.	1.2	4
403	Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse.. Journal of Clinical Oncology, 2014, 32, 5003-5003.	0.8	12
404	Risk-Based Prostate Cancer Screening: Who and How?. Current Urology Reports, 2013, 14, 192-198.	1.0	14
405	A longitudinal study of anxiety, depression and distress as predictors of sexual and urinary quality of life in men with prostate cancer. BJU International, 2013, 112, E67-75.	1.3	86
406	Factors associated with downgrading in patients with high grade prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 442-447.	0.8	9
407	Validation of a Cell-Cycle Progression Gene Panel to Improve Risk Stratification in a Contemporary Prostatectomy Cohort. Journal of Clinical Oncology, 2013, 31, 1428-1434.	0.8	323
408	Biomarkers in prostate cancer surveillance and screening: past, present, and future. Therapeutic Advances in Urology, 2013, 5, 318-329.	0.9	99
409	Management of Biochemical Recurrence After Primary Treatment of Prostate Cancer: A Systematic Review of the Literature. European Urology, 2013, 64, 905-915.	0.9	128
410	Reflex ImmunoCyt Testing for the Diagnosis of Bladder Cancer in Patients with Atypical Urine Cytology. European Urology, 2013, 63, 936-940.	0.9	32
411	Re: Quality-of-life Effects of Prostate-specific Antigen Screening. European Urology, 2013, 63, 1130.	0.9	0
412	Patient Demographics, Quality of Life, and Disease Features of Men With Newly Diagnosed Prostate Cancer: Trends in the PSA Era. Urology, 2013, 82, 60-66.	0.5	26
413	How does robot-assisted radical prostatectomy (<scp>RARP</scp>) compare with open surgery in men with high-risk prostate cancer?. BJU International, 2013, 112, E314-20.	1.3	56
414	Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study. Journal of Comparative Effectiveness Research, 2013, 2, 445-460.	0.6	59

#	ARTICLE	IF	CITATIONS
415	The epidemiology of high-risk prostate cancer. <i>Current Opinion in Urology</i> , 2013, 23, 331-336.	0.9	48
416	Expanding Utilization of Intensity-Modulated Radiotherapy for Prostate Cancer: Soaring Costs, Dubious Benefits. <i>JAMA Internal Medicine</i> , 2013, 173, 1143.	2.6	2
417	Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. <i>BJU International</i> , 2013, 111, 437-450.	1.3	109
418	Reply to A. Azad et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 3296-3297.	0.8	0
419	Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. <i>Prostate Cancer and Prostatic Diseases</i> , 2013, 16, 391-397.	2.0	53
420	Re-Examining Racial Disparities in Prostate Cancer Outcomes. <i>Journal of Clinical Oncology</i> , 2013, 31, 2979-2980.	0.8	20
421	Limitations of Basing Screening Policies on Screening Trials. <i>Medical Care</i> , 2013, 51, 295-300.	1.1	63
422	Divorcing Diagnosis From Treatment: Contemporary Management of Low-Risk Prostate Cancer. <i>Korean Journal of Urology</i> , 2013, 54, 417.	1.2	2
423	Proximal Bulbar Periurethral Abscess. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2013, 39, 137-138.	0.7	7
424	Comparative Effectiveness of Treatment Alternatives for Localized Prostate Cancer. , 2013, , 593-605.		0
425	High-risk nonmuscle invasive bladder cancer. <i>Current Opinion in Urology</i> , 2012, 22, 385-389.	0.9	2
426	Role of Active Surveillance in the Management of Localized Prostate Cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2012, 2012, 202-206.	0.9	13
427	New types of radiotherapy improve cancer outcome but at what cost?. <i>Nature Reviews Urology</i> , 2012, 9, 415-417.	1.9	0
428	PSA screening: determinants of primary-care physician practice patterns. <i>Prostate Cancer and Prostatic Diseases</i> , 2012, 15, 189-194.	2.0	22
429	Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram. <i>Prostate Cancer and Prostatic Diseases</i> , 2012, 15, 374-379.	2.0	32
430	Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2012, 15, 100-105.	2.0	37
431	Prostate Cancer Mortality following Active Surveillance versus Immediate Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2012, 18, 5471-5478.	3.2	52
432	FACTORS ASSOCIATED WITH TREATMENT RECEIVED BY MEN DIAGNOSED WITH PROSTATE CANCER IN QUEENSLAND, AUSTRALIA. <i>BJU International</i> , 2012, 110, E720.	1.3	0

#	ARTICLE	IF	CITATIONS
433	Active Surveillance for Prostate Cancer: A Systematic Review of the Literature. <i>European Urology</i> , 2012, 62, 976-983.	0.9	518
434	Will Biomarkers Save Prostate Cancer Screening?. <i>European Urology</i> , 2012, 62, 962-963.	0.9	5
435	Early Detection of Prostate Cancer: More Information, More Clarity. <i>European Urology</i> , 2012, 62, 753-755.	0.9	2
436	Reply to Jai Prakash, Apul Goel and Manish Garg's Letter to the Editor re: Anobel Y. Odisho, Anna B. Berry, Ardalan E. Ahmad, Matthew R. Cooperberg, Peter R. Carroll, Badrinath R. Konety. Reflex ImmunoCyt Testing for the Diagnosis of Bladder Cancer in Patients with Atypical Urine Cytology. <i>Eur Urol</i> . In press. http://dx.doi.org/10.1016/j.eururo.2012.04.019 . <i>European Urology</i> , 2012, 62, e88.	0.9	0
437	Outcomes for Radical Prostatectomy: Is It the Singer, the Song, or Both?. <i>Journal of Clinical Oncology</i> , 2012, 30, 476-478.	0.8	28
438	Editorial Comment. <i>Urology</i> , 2012, 80, 305-306.	0.5	1
439	Prostate specific antigen screening for prostate cancer: Knowledge of, attitudes towards, and utilization among primary care physicians. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 155-160.	0.8	38
440	Proton Beam Therapy and Treatment for Localized Prostate Cancer: If You Build It, They Will Come. <i>Archives of Internal Medicine</i> , 2012, 172, 280.	4.3	4
441	The quantitative Gleason score improves prostate cancer risk assessment. <i>Cancer</i> , 2012, 118, 6046-6054.	2.0	53
442	For localized prostate cancer, does technology equal progress?. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 371-372.	12.5	0
443	Adverse Effects of Androgen Deprivation and the Limits of National Tumor Registries. <i>European Urology</i> , 2012, 61, 701-703.	0.9	2
444	Thwarting High-risk Prostate Cancer: The Right Treatments for the Right Patients. <i>European Urology</i> , 2012, 61, 1107-1109.	0.9	3
445	To Predict the Future, Consider the Present as Well as the Past. <i>European Urology</i> , 2012, 62, 53-54.	0.9	1
446	Among potent men post radical prostatectomy, does the need for phosphodiesterase inhibitors have an impact on sexual bother scores?. <i>BJU International</i> , 2012, 109, 1520-1524.	1.3	4
447	External-beam radiation therapy should be given with androgen deprivation treatment for intermediate-risk prostate cancer: new confirmatory evidence. <i>Asian Journal of Andrology</i> , 2012, 14, 132-133.	0.8	0
448	Validation of a panel of cell-cycle progression genes for improved risk stratification in a contemporary radical prostatectomy cohort.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10-10.	0.8	0
449	Editorial Comment. <i>Urology</i> , 2011, 77, 1336-1337.	0.5	0
450	The Relationship Between Prostate Specific Antigen Change and Biopsy Progression in Patients on Active Surveillance for Prostate Cancer. <i>Journal of Urology</i> , 2011, 185, 1656-1660.	0.2	103

#	ARTICLE	IF	CITATIONS
451	Treatment Trends for Stage I Renal Cell Carcinoma. <i>Journal of Urology</i> , 2011, 186, 394-399.	0.2	95
452	High-risk prostate cancer: treat the prostate. <i>Lancet</i> , The, 2011, 378, 2056-2057.	6.3	3
453	Re: Radical Prostatectomy Versus Watchful Waiting in Early Prostate Cancer. <i>European Urology</i> , 2011, 60, 868-869.	0.9	0
454	The example of CaPSURE: lessons learned from a national disease registry. <i>World Journal of Urology</i> , 2011, 29, 265-271.	1.2	32
455	Inaccuracies in assignment of clinical stage for localized prostate cancer. <i>Cancer</i> , 2011, 117, 283-289.	2.0	59
456	Reply to comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. <i>Cancer</i> , 2011, 117, 3532-3533.	2.0	1
457	Impact of androgen deprivation on physical well-being in patients with prostate cancer. <i>Cancer</i> , 2011, 117, 4406-4413.	2.0	29
458	The CAPRA score. <i>Cancer</i> , 2011, 117, 5039-5046.	2.0	359
459	Changes in Prostate Cancer Grade on Serial Biopsy in Men Undergoing Active Surveillance. <i>Journal of Clinical Oncology</i> , 2011, 29, 2795-2800.	0.8	177
460	Prediction of Erectile Function Following Treatment for Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1205.	3.8	253
461	Serum Prostate-Specific Antigen for the Early Detection of Prostate Cancer: Always, Never, or Only Sometimes?. <i>Journal of Clinical Oncology</i> , 2011, 29, 345-347.	0.8	23
462	Androgen Deprivation Therapy and Cardiovascular Risk. <i>Journal of Clinical Oncology</i> , 2011, 29, 3510-3516.	0.8	70
463	Reply to M. Froehner. <i>Journal of Clinical Oncology</i> , 2011, 29, e282-e282.	0.8	0
464	Outcomes of Active Surveillance for Men With Intermediate-Risk Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 228-234.	0.8	259
465	Impact of Age at Diagnosis on Prostate Cancer Treatment and Survival. <i>Journal of Clinical Oncology</i> , 2011, 29, 235-241.	0.8	321
466	Active Surveillance for Prostate Cancer: Progress and Promise. <i>Journal of Clinical Oncology</i> , 2011, 29, 3669-3676.	0.8	264
467	Robot-Assisted Radical Prostatectomy: A Prostate Surgeon's Perspective. , 2011, , 255-260.		0
468	Gender differences in subcutaneous and perirenal fat distribution. <i>Surgical and Radiologic Anatomy</i> , 2010, 32, 879-882.	0.6	51

#	ARTICLE	IF	CITATIONS
469	Electronic patient self-assessment and management (SAM): a novel framework for cancer survivorship. <i>BMC Medical Informatics and Decision Making</i> , 2010, 10, 34.	1.5	32
470	Prognostic Implications of an Undetectable Ultrasensitive Prostate-Specific Antigen Level after Radical Prostatectomy. <i>European Urology</i> , 2010, 57, 622-630.	0.9	54
471	Reply to Piet Ost, Alberto Bossi and Gert De Meerleer's Letter to the Editor re: Michael L. Eisenberg, Benjamin J. Davies, Matthew R. Cooperberg, et al. Prognostic Implications of an Undetectable Ultrasensitive Prostate-Specific Antigen Level after Radical Prostatectomy. <i>Eur Urol</i> 2010;57:622-30. <i>European Urology</i> , 2010, 58, e34-e35.	0.9	0
472	Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen deprivation therapy for localized prostate cancer. <i>Cancer</i> , 2010, 116, 5226-5234.	2.0	286
473	Adequacy of lymphadenectomy among men undergoing robot-assisted laparoscopic radical prostatectomy. <i>BJU International</i> , 2010, 105, 88-92.	1.3	53
474	The independent value of tumour volume in a contemporary cohort of men treated with radical prostatectomy for clinically localized disease. <i>BJU International</i> , 2010, 105, 472-475.	1.3	37
475	Changes in specific domains of sexual function and sexual bother after radical prostatectomy. <i>BJU International</i> , 2010, 106, 1022-1029.	1.3	42
476	Specialist visits (urologist, radiation oncologist, medical oncologist) are strongly associated with treatment received for prostate cancer in the USA. <i>Evidence-Based Medicine</i> , 2010, 15, 95-96.	0.6	1
477	Urologist Density and County-Level Urologic Cancer Mortality. <i>Journal of Clinical Oncology</i> , 2010, 28, 2499-2504.	0.8	78
478	In Vivo Tumor Grading of Prostate Cancer Using Quantitative ¹¹¹ In-Capromab Pendetide SPECT/CT. <i>Journal of Nuclear Medicine</i> , 2010, 51, 31-36.	2.8	29
479	Adequacy of a Single 24-Hour Urine Collection for Metabolic Evaluation of Recurrent Nephrolithiasis. <i>Journal of Urology</i> , 2010, 184, 579-583.	0.2	33
480	Minimal Impact of Clinical Stage on Prostate Cancer Prognosis Among Contemporary Patients With Clinically Localized Disease. <i>Journal of Urology</i> , 2010, 184, 114-119.	0.2	39
481	Time Trends and Local Variation in Primary Treatment of Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1117-1123.	0.8	917
482	Disproportionate Presentation of High Risk Prostate Cancer in a Safety Net Health System. <i>Journal of Urology</i> , 2010, 184, 1931-1936.	0.2	20
483	Are Age-Based Criteria the Best Way to Determine Eligibility for Prostate Cancer Screening?. <i>Annals of Internal Medicine</i> , 2009, 150, 220.	2.0	7
484	Risk Assessment Among Prostate Cancer Patients Receiving Primary Androgen Deprivation Therapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 4306-4313.	0.8	115
485	Risk Assessment for Prostate Cancer Metastasis and Mortality at the Time of Diagnosis. <i>Journal of the National Cancer Institute</i> , 2009, 101, 878-887.	3.0	287
486	Candidate quality of care indicators for localized bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 435-442.	0.8	35

#	ARTICLE	IF	CITATIONS
487	Defining high quality health care. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 411-416.	0.8	30
488	NATIONAL TRENDS IN TREATMENT OF STAGE I RENAL CELL CARCINOMA. Journal of Urology, 2009, 181, 319-319.	0.2	8
489	Patients With Primary Hyperparathyroidismâ€”Why Do Some Form Stones?. Journal of Urology, 2009, 181, 2141-2145.	0.2	49
490	Geographic Distribution of Urologists Throughout the United States Using a County Level Approach. Journal of Urology, 2009, 181, 760-766.	0.2	79
491	Improper Retrograde Urethrogram Technique Leads to Incorrect Diagnosis. Journal of Urology, 2009, 182, 716-717.	0.2	20
492	Management of localized prostate cancer in men over 65 years. Current Opinion in Urology, 2009, 19, 309-314.	0.9	15
493	Prostate-cancer screening. New England Journal of Medicine, 2009, 361, 203; author reply 204-5.	13.9	5
494	High-risk prostate cancer in the United States, 1990â€”2007. World Journal of Urology, 2008, 26, 211-218.	1.2	173
495	Active surveillance for earlyâ€”stage prostate cancer. Cancer, 2008, 112, 1650-1659.	2.0	252
496	Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer, 2008, 112, 2664-2670.	2.0	361
497	Renal cell cancer stage migration. Cancer, 2008, 113, 78-83.	2.0	535
498	Prostate cancer risk assessment. Cancer, 2008, 113, 3062-3066.	2.0	16
499	THE UCSF CANCER OF THE PROSTATE RISK ASSESSMENT (CAPRA) SCORE ACCURATELY PREDICTS METASTASIS, PROSTATE CANCER MORTALITY, AND ALL-CAUSE MORTALITY REGARDLESS OF TREATMENT TYPE. Journal of Urology, 2008, 179, 114-115.	0.2	2
500	PROSTATE TUMOR VOLUME DOES NOT INDEPENDENTLY PREDICT OUTCOME FOLLOWING RADICAL PROSTATECTOMY. Journal of Urology, 2008, 179, 194-194.	0.2	0
501	Decreasing Size at Diagnosis of Stage 1 Renal Cell Carcinoma: Analysis From the National Cancer Data Base, 1993 to 2004. Journal of Urology, 2008, 179, 2131-2135.	0.2	91
502	Health Related Quality of Life in Patients Treated With Multimodal Therapy for Prostate Cancer. Journal of Urology, 2008, 180, 2415-2422.	0.2	49
503	POSTERIOR TIBIAL NERVE STIMULATION FOR PELVIC FLOOR DYSFUNCTION. , 2008, , 277-283.		2
504	Urinary Citrate Levels Do Not Correlate with Urinary pH in Patients with Urinary Stone Formation. Urology, 2007, 70, 634-637.	0.5	9

#	ARTICLE	IF	CITATIONS
505	Urethral Reconstruction for Traumatic Posterior Urethral Disruption: Outcomes of a 25-Year Experience. <i>Journal of Urology</i> , 2007, 178, 2006-2010.	0.2	127
506	Trends in Regionalization of Inpatient Care for Urological Malignancies, 1988 to 2002. <i>Journal of Urology</i> , 2007, 178, 2103-2108.	0.2	51
507	Contemporary Trends in Low Risk Prostate Cancer: Risk Assessment and Treatment. <i>Journal of Urology</i> , 2007, 178, S14-9.	0.2	368
508	Oral calcium supplementation associated with decreased likelihood of nephrolithiasis prior to surgery for hyperparathyroidism. <i>International Journal of Urology</i> , 2007, 14, 1113-1115.	0.5	6
509	1362: Nephrolithiasis and the Risk of Cardiovascular Disease. <i>Journal of Urology</i> , 2007, 177, 449-449.	0.2	4
510	The Art and Science of Risk Stratification in Localized Prostate Cancer. <i>Seminars in Preventive and Alternative Medicine</i> , 2007, 3, 101-105.	0.1	0
511	Differences in clinical characteristics and disease-free survival for Latino, African American, and non-Latino white men with localized prostate cancer. <i>Cancer</i> , 2006, 106, 789-795.	2.0	50
512	Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. <i>Cancer</i> , 2006, 107, 2384-2391.	2.0	129
513	1105: Stage Migration in Renal Cell Carcinoma Patients Demonstrated by Analysis of the National Cancer Database, 1993-2003. <i>Journal of Urology</i> , 2006, 175, 355-355.	0.2	1
514	The Changing Face of Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 8146-8151.	0.8	293
515	Variability in testis biopsy interpretation: implications for male infertility care in the era of intracytoplasmic sperm injection. <i>Fertility and Sterility</i> , 2005, 84, 672-677.	0.5	32
516	Laparoscopic management of peripelvic renal cysts: University of California, San Francisco, experience and review of literature. <i>Urology</i> , 2005, 65, 882-887.	0.5	50
517	ABILITY OF 2 PRETREATMENT RISK ASSESSMENT METHODS TO PREDICT PROSTATE CANCER RECURRENCE AFTER RADICAL PROSTATECTOMY: DATA FROM CaPSURE. <i>Journal of Urology</i> , 2005, 173, 1126-1131.	0.2	69
518	Percutaneous neuromodulation. <i>Urologic Clinics of North America</i> , 2005, 32, 71-78.	0.8	76
519	OBESITY AND PROSTATE CANCER CLINICAL RISK FACTORS AT PRESENTATION: DATA FROM CaPSURE. <i>Journal of Urology</i> , 2005, 173, 732-736.	0.2	53
520	THE IMPACT OF OBESITY ON HEALTH RELATED QUALITY OF LIFE BEFORE AND AFTER RADICAL PROSTATECTOMY (DATA FROM CaPSURE). <i>Journal of Urology</i> , 2005, 173, 1132-1138.	0.2	62
521	THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CANCER OF THE PROSTATE RISK ASSESSMENT SCORE: A STRAIGHTFORWARD AND RELIABLE PREOPERATIVE PREDICTOR OF DISEASE RECURRENCE AFTER RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2005, 173, 1938-1942.	0.2	592
522	Impact of obesity on prostate cancer recurrence after radical prostatectomy: Data from CaPSURE. <i>Urology</i> , 2005, 66, 1060-1065.	0.5	135

#	ARTICLE	IF	CITATIONS
523	Who is the average patient presenting with prostate cancer?. Urology, 2005, 66, 76-82.	0.5	43
524	The Changing Face of Low-Risk Prostate Cancer: Trends in Clinical Presentation and Primary Management. Journal of Clinical Oncology, 2004, 22, 2141-2149.	0.8	528
525	Mapping Tumor Epitope Space by Direct Selection of Single-Chain Fv Antibody Libraries on Prostate Cancer Cells. Cancer Research, 2004, 64, 704-710.	0.4	90
526	Patterns of practice in the United States: Insights from CaPSURE on prostate cancer management. Current Prostate Reports, 2004, 2, 5-11.	0.1	0
527	Patterns of practice in the United States: Insights from CaPSURE on prostate cancer management. Current Urology Reports, 2004, 5, 166-172.	1.0	29
528	THE CONTEMPORARY MANAGEMENT OF PROSTATE CANCER IN THE UNITED STATES: LESSONS FROM THE CANCER OF THE PROSTATE STRATEGIC UROLOGIC RESEARCH ENDEAVOR (CAPSURE), A NATIONAL DISEASE REGISTRY. Journal of Urology, 2004, 171, 1393-1401.	0.2	315
529	VALIDATION OF THE KATTAN PREOPERATIVE NOMOGRAM FOR PROSTATE CANCER RECURRENCE USING A COMMUNITY BASED COHORT: RESULTS FROM CANCER OF THE PROSTATE STRATEGIC UROLOGICAL RESEARCH ENDEAVOR (CAPSURE). Journal of Urology, 2004, 171, 2255-2259.	0.2	100
530	Radical retropubic prostatectomy frustrated by prior laparoscopic mesh herniorrhaphy. Surgery, 2004, 135, 452-453.	1.0	38
531	Prostate cancer 2004: insights from national disease registries. Oncology, 2004, 18, 1239-47; discussion 1248-50, 1256-8.	0.4	22
532	Health Related Quality of Life Significance of Single Pad Urinary Incontinence Following Radical Prostatectomy. Journal of Urology, 2003, 170, 512-515.	0.2	54
533	Sociodemographic and Clinical Risk Characteristics of Patients With Prostate Cancer Within the Veterans Affairs Health Care System: Data From CaPSURE. Journal of Urology, 2003, 170, 905-908.	0.2	38
534	Time Trends and Characteristics of Men Choosing Watchful Waiting for Initial Treatment of Localized Prostate Cancer: Results From CaPSURE. Journal of Urology, 2003, 170, 1804-1807.	0.2	125
535	Time Trends in Clinical Risk Stratification for Prostate Cancer: Implications for Outcomes (Data From) Tj ETQq1 1 0.784314 rgBT /Ove 0.2 270	0.2	270
536	How potent is potent? Evaluation of sexual function and bother in men who report potency after treatment for prostate cancer:data from CaPSURE. Urology, 2003, 61, 190-196.	0.5	65
537	Evolving Indications for Active Surveillance in Low-Risk Localized Prostate Cancer. European Urology Supplements, 2003, 2, 7-13.	0.1	1
538	National Practice Patterns and Time Trends in Androgen Ablation for Localized Prostate Cancer. Journal of the National Cancer Institute, 2003, 95, 981-989.	3.0	323
539	The evolving role of androgen deprivation therapy in the management of prostate cancer. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2003, 55, 219-38.	3.9	8
540	Contemporary Trends in Imaging Test Utilization for Prostate Cancer Staging: Data from the Cancer of the Prostate Strategic Urologic Research Endeavor. Journal of Urology, 2002, 168, 491-495.	0.2	69

#	ARTICLE	IF	CITATIONS
541	Contemporary Trends in Imaging Test Utilization for Prostate Cancer Staging:. Journal of Urology, 2002, , 491-495.	0.2	1
542	Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavor. Journal of Urology, 2002, 168, 491-5.	0.2	15
543	Ki-1 anaplastic large-cell lymphoma occurring at the site of ileocolonic anastomosis in a patient treated surgically for colonic adenocarcinoma: Case report and review of the literature. Annals of Diagnostic Pathology, 2001, 5, 162-167.	0.6	16
544	Stroke in surgery of the thoracic aorta: Incidence, impact, etiology, and prevention. Journal of Thoracic and Cardiovascular Surgery, 2001, 122, 935-945.	0.4	88
545	Methods for Chemoprotection and Chemosensitization MDR-1 For Chemoprotection Using Retroviruses to Modify Hematopoietic Cells and Cytosine Deaminase for Chemosensitization Using Adenoviral Vectors to Modify Epithelial Neoplastic Cells. , 2000, 35, 609-616.		0
546	Cystic pelvic pathology presenting as falsely elevated postvoid residual urine measured by portable ultrasound bladder scanning: report of 3 cases and review of the literature. Urology, 2000, 55, 590.	0.5	32
547	Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation. Blood, 1998, 92, 672-82.	0.6	19
548	Multidrug resistance and prodrug activation for cancer gene therapy of breast cancer. Breast Cancer, 1997, 4, 210-212.	1.3	0
549	Validation of the prostate cancer comorbidity index in predicting cause-specific mortality in men undergoing radical prostatectomy. Prostate Cancer and Prostatic Diseases, 0, , .	2.0	1
550	Radium-223 Utilization Patterns and Outcomes in Clinical Practice. Urology Practice, 0, , .	0.2	0